6 registrations that name cetrorelix as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 6 registrations
Status
Phase
All 6 registrations
RecruitingNCT06023602
Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone（GnRH）Antagonist Protocol in Women Undergoing IVF
No phase
Northwest Women's and Children's Hospital, Xi'an, Shaanxi
About 1,338 people
Started Feb 27, 2024
In plain words A study of cetrorelix in female participants 20 to 42, run by Northwest Women's and Children's Hospital, Xi'an, Shaanxi. It plans to enroll about 1,338 people at 1 site, none in the US.
The goal of this clinical trial is to compare the clinical outcomes using different cetrorelix acetate in the context of a GnRH antagonist protocol for ovarian stimulation in women undergoing IVF or intracytoplasmic sperm injection(ICSI) treatment.The main question it aims to answer is whether the generic cetrorelix acetate is non-inferior to the reference product in the GnRH antagonist based protocol for women undergoing IVF. Ovarian stimulation was achieved by several types of follicle-stimulating hormone(FSH) or by FSH combined with luteinizing hormone activity. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT07340827
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
Phase 3
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
About 266 people
Started Feb 4, 2026
In plain words A Phase 3 study of cetrorelix in female participants 18 to 42, run by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. It plans to enroll about 266 people at 21 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 42. Conditions: Infertility.
Participants who are premenopausal wishing to conceive
Participants with maximum 1 previous stimulation for assisted reproductive technology (ART) without pregnancy
Japanese Participants
Participants are women with Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) deficiency congenital or acquired
4 more inclusion criteria and the exclusion criteria are on the listing.
The purpose of this study is to assess the efficacy and safety of follitropin alfa/lutropin alfa in Japanese participants with Luteinizing hormone (LH) and Follicle stimulating hormone (FSH) deficiency undergoing Assisted reproductive technology (ART). The study duration is approximately 5.5 months for nonpregnant participants and 13 months for participants with confirmed pregnancy in Part A.
Where, as registered
No US site; Japan (21).
Not yet recruitingNCT07350317
Trial Comparing Subcutaneous Natural Progesterone (Prolutex) vs. Cetrorelix Acetate for Luteinizing Hormone Surge Suppression in Freeze-All IVF Cycles.
Phase 4
Trust Fertility Clinic
About 230 people
Starts Jan 2026 (estimated)
In plain words A Phase 4 study of cetrorelix in female participants 18 to 40, run by Trust Fertility Clinic. It plans to enroll about 230 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 40. Conditions: Assisted Reproductive Techniques.
Undergoing freeze-all IVF (for Ovarian Hyperstimulation Syndrome - OHSS risk, PGT- Preimplantation Genetic Testing, or personal preference)
The exclusion criteria are on the listing.
What it tests, as registered
Control Group (A):; Test Group (B):
Registered summary
The prevention of premature luteinizing hormone (LH) surge during controlled ovarian stimulation (COS) is critical for optimizing outcomes in assisted reproductive technology (ART). Cetrorelix acetate, a GnRH (Gonadotropin releasing hormone) antagonist administered subcutaneously, is the current standard for luteinizing hormone suppression. However, natural progesterone in a novel subcutaneous formulation (Prolutex) may offer a viable alternative. Prolutex is a water-soluble complex of natural progesterone with hydroxypropyl-β-cyclodextrin (HPBCD), patented as US Patent No. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT05326087
Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A
Phase 3
ShangHai Ji Ai Genetics & IVF Institute
About 204 people
Starts Jun 1, 2026 (estimated)
In plain words A Phase 3 study of cetrorelix in female participants 20 to 37, run by ShangHai Ji Ai Genetics & IVF Institute. It plans to enroll about 204 people and lists no sites yet.
Women diagnosed with PCOS according to the modified Rotterdam criteria: oligomenorrhea or amenorrhea, together with the presence of ≥12 antral follicles (≤9 mm) and/or ovarian volume >10 mL on transvaginal ultrasonographic scanning, and/or…
The exclusion criteria are on the listing.
What it tests, as registered
GnRH antagonist; MPA
Registered summary
This randomized trial aims to compare the euploid rate of blastocysts between PPOS (progestin-primed ovarian stimulation) and GnRH (gonadotrophin releasing hormone) antagonist protocols in patients with PCOS (polycystic ovary syndrome) undergoing PGT-A (preimplantation genetic testing for aneuploidy). Infertile women with PCOS will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07732348
Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist in Controlled Ovarian Stimulation for In Vitro Fertilization: A Randomized Controlled Non-Inferiority Trial With a Concurrent Comparator Cohort Undergoing Progestin-Primed Ovarian Stimulation (PPOS)
No phase
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita)
About 120 people
Starts Sep 2026 (estimated)
In plain words A study of cetrorelix in female participants 18 to 42, run by Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita). It plans to enroll about 120 people and lists no sites yet.
Women undergoing IVF/ICSI who are candidates for a GnRH-antagonist protocol are randomly assigned 1:1 to oral linzagolix or the standard injectable GnRH antagonist (ganirelix or cetrorelix). A third, non-randomized group of women with a clinical indication for progestin-primed ovarian stimulation (PPOS) - for example, a need for a freeze-all strategy - is enrolled concurrently as a comparator cohort. The randomized comparison (linzagolix vs. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07736261
Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF/ICSI
Phase 1 and 2
Ahmed Saad
About 100 people
Starts Aug 2026 (estimated)
In plain words A Phase 1 and 2 study of cetrorelix in female participants 20 to 42, run by Ahmed Saad. It plans to enroll about 100 people at 1 site, none in the US.
Poor ovarian response per Bologna criteria (≥2 of 3): advanced age ≥40 or risk factor for POR; previous poor response (≤3 oocytes with conventional stimulation); abnormal ovarian reserve (AFC <7 or AMH <1.1 ng/mL)
POSEIDON group recorded at enrollment (1-4) for stratified randomization and pre-specified subgroup description - corrects a known limitation of Bologna-only classification, which pools biologically distinct POR phenotypes
Indication for IVF/ICSI
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Drospirenone drug; Cetrorelix 0.25 mg
Registered summary
Participants will: * Take either drospirenone (a daily pill) or the standard daily injection during their ovarian stimulation cycle, alongside their regular fertility hormone injections * Undergo egg retrieval, with all resulting embryos frozen (no fresh embryo transfer in this study) * Have a frozen embryo transferred in a later cycle * Complete two short questionnaires about their treatment experience - once before starting the injections/pills, and once after the stimulation phase ends * Be followed to determine if the embryo transfer results in a pregnancy